Prof. Yanfang Zheng 郑燕芳
Chief Physician, Professor
Department of Medical Oncology, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, biological therapy, and targeted therapy for malignant tumors, with a focus on lung cancer, breast cancer, esophageal cancer, and colorectal cancer.
Dr. Zheng holds a medical doctorate and completed postdoctoral training at the US National Institutes of Health (2004). Dr. Zheng served as a Research Assistant Professor at George Mason University (2008), completed residency at York Hospital, and holds a US medical license. Currently Director of Medical Oncology, Dr. Zheng leads research funded by the National Natural Science Foundation and has published over 50 papers.
Professional roles
- Vice Chair and Secretary-General, Tumor Targeted Therapy Technology Branch, Chinese Society of Biomedical Engineering
- Vice Chair and Secretary-General, Guangdong Cell Biology Society
- Secretary-General, Guangdong Association for Tumor Targeted Intervention and Prevention
- Member, American Medical Association
Name order: in Chinese the family name comes first (Zheng Yanfang). Papers usually list the name as Yanfang Zheng or Zheng Y.
Selected publications
20 papers on PubMed matched by name and affiliation; 16 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Gastrointestin Liver Dis, 2026 (senior author): Clarithromycin Resistance Patterns of Helicobacter pylori across Different Gastric Diseases in Uzbekistan. PubMed 42365653
- J Immunother Cancer, 2026 (senior author): Targeting VEGF signaling and stromal remodeling enhances chemoimmunotherapy efficacy in esophageal cancer. PubMed 42173653
- NPJ Digit Med, 2025 (senior author): GLANCE: continuous global-local exchange with consensus fusion for robust nodule segmentation. PubMed 41469800
- Bioact Mater, 2025 (senior author): Inhibition of ARH2 by pH/ROS-responsive nanosystem for improved lung adenocarcinoma immunochemotherapy. PubMed 40801020
- Cell Death Discov, 2025 (senior author): Circular RNA circLIMK1-005 promotes the progression of lung adenocarcinoma by interacting with RPA1 protein to activate CDK4 signaling. PubMed 40593477
- J Gastrointest Oncol, 2024 (senior author): Senescence-related signatures predict prognosis and response to immunotherapy in colon cancer. PubMed 38989417
- Transl Cancer Res, 2024 (senior author): Synergistic action of gemcitabine and celecoxib in promoting the antitumor efficacy of anti-programmed death-1 monoclonal antibody by triggering immunogenic cell death. PubMed 38988937
- J Nanobiotechnology, 2024 (senior author): NIR-responsive CN-Pt-GEM hydrogel induces necroptosis and immunotherapeutic responses prevent postoperative recurrence and wound infection in lung carcinoma. PubMed 38902678
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion